FDA Shocker: Unpacking the Controversial Drug Approval Rejection

Join Daniel and Cody as they dive into the shocking news from the FDA's advisory committee review. We'll set the stage with an in-depth look at the independent panels of researchers, insurance executives, and doctors who play a crucial role in drug approval. Discover why the MAPS program, integrating psychotherapy with new drug trials, has turned the review process upside down. They'll discuss the controversies, including trial design issues, racial disparities among participants, and the surprising rejection of a breakthrough PTSD treatment. Is there a deeper bias within the FDA, or is it a matter of incompetence from the drug development team at Lycos Therapeutics?  Explore the impact on veterans and PTSD survivors, the future of therapies like MDMA and ketamine, and how companies like Healing Realty Trust are navigating these turbulent waters. Tune in for a critical analysis and personal opinions on the FDA's decision, its implications for mental health treatment, and what it means for the future of drug development and approval.